Codexis Inc (CDXS NASDAQ) stock market data APIs
$1.7085
0.23(13.5%)
as of March 12, 2026
Try our APIs with
free plan!
Codexis Inc Financial Data Overview
Price chart is built with
Anychart
Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Prev. Close
1.7085
Open
1.9348
High
2.1342
Low
1.6249
52 wk Range
0.9583-3.87
Market Cap
154 M
Shares Outstanding
90 324 K
Revenue
70 387 K
EPS
0.143
Beta
2.502
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Codexis Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Codexis Inc data using free add-ons & libraries
Get Codexis Inc Fundamental Data
Codexis Inc Fundamental data includes:
- Net Revenue: 70 387 K
- EBITDA: -33 144 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-26
- EPS/Forecast: -0.0371
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Codexis Inc News
New
Codexis, Inc. Q4 2025 Earnings Call Summary
Codexis, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Execution and Platform Validation Shifted the ECOsynthesis platform from technical feasibility to supporting preclinical development, tar...
Codexis outlines $72M–$76M 2026 revenue target as ECO Synthesis gains momentum and CDMO partnerships expand
Earnings Call Insights: Codexis (CDXS) Q4 2025 MANAGEMENT VIEW * CEO Alison Moore stated that Codexis is now focused on RNA medicine and has developed the ECO Synthesis manufacturing platform to a...
Codexis Q4 Earnings Call Highlights
Codexis logo Key Points Codexis is focused on scaling its ECO Synthesis enzymatic siRNA platform, hitting a 2025 milestone by synthesizing 10 grams of a commercially relevant siRNA, operating at 100...
Codexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11
Codexis, Inc. REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex thera...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
